CDK4/6 inhibitors (palbociclib) slow AML progression by reducing DNA damage and telomere shortening in T cells by inhibiting CDK4 and CDK6 kinase activities (Nebenfuehr et al., 2020; Schmoellerl et al., 2020). This evidence concerns the gene CDK6 and acute myeloid leukemia.